Gilead Sciences Inc stock is traded at $168.08, with a volume of 3,627,692. It is up +0.08% in the last 24 hours and up +13.63% over the past month. Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Previous Close:
$167.95
Open:
$168.58
24h Volume:
3,627,692
Relative Volume:
0.56
Market Cap:
$208.48B
Revenue:
$29.79B
Net Income/Loss:
$9.22B
P/E Ratio:
22.87
EPS:
$7.35
Net Cash Flow:
$10.23B
1W Performance:
+0.71%
1M Performance:
+13.63%
6M Performance:
+26.33%
1Y Performance:
+34.25%
1-Day Range:
$166.94$169.12
1-Week Range:
$165.99$171.70
52-Week Range:
$116.88$176.58
Gilead Sciences Inc Stock (GILD) Company Profile
Name
Gilead Sciences IncSector
HealthcareIndustry
Drug Manufacturers - GeneralPhone
(650) 574-3000Address
333 LAKESIDE DR, FOSTER CITY, CA, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS